Literature DB >> 8568873

Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.

R Schier1, J Bye, G Apell, A McCall, G P Adams, M Malmqvist, L M Weiner, J D Marks.   

Abstract

The use of antibodies to target tumor antigens has had limited success, partially due to the large size of IgG molecules, difficulties in constructing smaller single chain Fv (scFv) antibody fragments, and immunogenicity of murine antibodies. These limitations can be overcome by selecting human scFv directly from non-immune or semi-synthetic phage antibody libraries; however, the affinities are typically too low for therapeutic application. For hapten antigens, higher-affinity scFv can be isolated from phage antibody libraries where the VH and VL genes of a binding scFv are replaced with repertoires of V genes (chain shuffling). The applicability of this approach to protein binding scFv is unknown. For this work, chain shuffling was used to increase the affinity of a non-immune human scFv, which binds the glycoprotein tumor antigen c-erbB-2 with an affinity of 1.6 x 10(-8) M. The affinity of the parental scFv was increased sixfold (Kd = 2.5 x 10(-9) M) by light-chain shuffling and fivefold (Kd = 3.1 x 10(-9) M) by heavy-chain shuffling, values comparable to those for antibodies against the same antigen produced by hybridomas. When selections were performed on antigen immobilized on polystyrene, spontaneously dimerizing scFv were isolated, the best of which had only a slightly lower Kd than wild type (Kd = 1.1 x 10(-8) M). These scFv dimerize on phage and are preferentially selected as a result of increased avidity. Compared to scFv which formed only monomer, dimerizing scFv had mutations located at the VH-VL interface, suggesting that VH-VL complementarity determines the extent of dimerization. Higher-affinity monomeric scFv were only obtained by selecting in solution using limiting concentrations of biotinylated antigen, followed by screening mutant scFv from bacterial periplasm by koff in a BIAcore. Using the proper selection and screening conditions, protein binding human scFv with affinities comparable to murine hybridomas can be produced without immunization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568873     DOI: 10.1006/jmbi.1996.0004

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  69 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

Authors:  J M Lecerf; T L Shirley; Q Zhu; A Kazantsev; P Amersdorfer; D E Housman; A Messer; J S Huston
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

3.  Antibodies with infinite affinity.

Authors:  A J Chmura; M S Orton; C F Meares
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

4.  Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.

Authors:  B P Mullaney; M G Pallavicini; J D Marks
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.

Authors:  E T Boder; K S Midelfort; K D Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 6.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 7.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

8.  Integrated mimicry of B cell antibody mutagenesis using yeast homologous recombination.

Authors:  Jeffrey S Swers; Yik A Yeung; K Dane Wittrup
Journal:  Mol Biotechnol       Date:  2011-01       Impact factor: 2.695

9.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins.

Authors:  Christopher Y Chen; Shannon M May; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

10.  Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics.

Authors:  H J de Haard; B Kazemier; M J Koolen; L J Nijholt; R H Meloen; B van Gemen; H R Hoogenboom; J W Arends
Journal:  Clin Diagn Lab Immunol       Date:  1998-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.